CEBPA and intrahepatic cholangiocarcinoma: Both the ICC and WHO 2022 classifications recognize CEBPA-mutated AML as a distinct entity, but differ in scope: the ICC includes only AML cases with in-frame bZIP domain mutations (allowing a lower blast count ≥10%) [2,47].